Literature DB >> 20303337

Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test.

Mikhail Kalinichev1, Kathryn R Starr, Simon Teague, Andrea M Bradford, Rod A Porter, Hugh J Herdon.   

Abstract

Glycine can act as either an inhibitory neurotransmitter or as a potentiator of NMDA-dependent excitatory neurotransmission. There is some evidence that glycine can have both pro- and anticonvulsant properties in various rodent models of epilepsy. In the present study we tested several glycine transporter 1 (GlyT1) inhibitors including NFPS, SSR 504734, Lu AA21279, Org 25935, SB-710622, GSK931145, as well as the glycine agonist d-serine, in the maximal electroshock threshold (MEST) test in the rat. In a series of experiments, male Sprague-Dawley rats (n=12/group) were pre-treated with a compound of interest and then received an electric shock delivered via corneal electrodes. A cohort of satellite animals (n=3/group) was also used to measure blood and brain levels of Org 25935. All GlyT1 inhibitors increased seizure thresholds dose-dependently, indicative of anticonvulsant activity. SB-710622 and GSK931145 had lower minimum effective doses (MEDs) in the MEST test than other GlyT1 inhibitors. At estimated t(max), increases in dose administered were paralleled by increases in blood and brain concentrations of Org 25935. Thus, increasing extracellular concentration of glycine via inhibition of its uptake protects from electroshock-induced seizures in the rat. Whether strychnine-sensitive or strychnine-insensitive glycine binding sites are involved in this effect remains to be determined. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303337     DOI: 10.1016/j.brainres.2010.03.032

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.

Authors:  Kent Jardemark; Monica M Marcus; Anna Malmerfelt; Mohammed Shahid; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2011-11-09       Impact factor: 4.530

2.  Glycine transporter 1 is a target for the treatment of epilepsy.

Authors:  Hai-Ying Shen; Erwin A van Vliet; Kerry-Ann Bright; Marissa Hanthorn; Nikki K Lytle; Jan Gorter; Eleonora Aronica; Detlev Boison
Journal:  Neuropharmacology       Date:  2015-08-21       Impact factor: 5.250

Review 3.  Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Authors:  Robert J Harvey; Benjamin K Yee
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

Review 4.  Metabolomics Provides Novel Insights into Epilepsy Diagnosis and Treatment: A Review.

Authors:  Wanlin Lai; Dan Du; Lei Chen
Journal:  Neurochem Res       Date:  2022-01-24       Impact factor: 3.996

5.  Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model.

Authors:  Amir Mohammadzadeh; Péter P Lakatos; Mihály Balogh; Ferenc Zádor; Dávid Árpád Karádi; Zoltán S Zádori; Kornél Király; Anna Rita Galambos; Szilvia Barsi; Pál Riba; Sándor Benyhe; László Köles; Tamás Tábi; Éva Szökő; Laszlo G Harsing; Mahmoud Al-Khrasani
Journal:  Int J Mol Sci       Date:  2021-03-01       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.